Coherus BioSciences appoints Rita A. Karachun to Board of Directors

Coherus Oncology, Inc.

Board size increased from 10 to 11; Karachun appointed as Class II director effective May 31, 2024.
To serve on Audit Committee; received option for 168,000 shares vesting over 3 years.
Previously SVP & Global Controller at Merck & Co. (2014-2023).
Annual cash retainer of $60k for board and audit committee service.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Rita A. Karachun

Class II Director

CHRS · Coherus Oncology, Inc.

Effective: 2024-05-31
Filed: June 5, 2024, 7:59 PM ET

the vacancy on the Board created by such increase would be filled by the appointment of Rita A. Karachun, with such appointment becoming effective upon the receipt of certain confirmations, which were received May 31, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Rita A. Karachun was appointed as Class II Director at Coherus Oncology, Inc..

Action: appointed
Role: Class II Director

Exact text from the filing

the vacancy on the Board created by such increase would be filled by the appointment of Rita A. Karachun, with such appointment becoming effective upon the receipt of certain confirmations, which were received May 31, 2024.

View on SEC.gov

Coherus Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-008918

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.